{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:02:22Z","timestamp":1789754542677,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.radonc.2026.111494","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:44:30Z","timestamp":1773906270000},"page":"111494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-9080","authenticated-orcid":false,"given":"Yoshiyuki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4967-6736","authenticated-orcid":false,"given":"Yuya","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-3670","authenticated-orcid":false,"given":"Nozomu","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichiro","family":"Saze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111494_b0005","unstructured":"Drugs.com. Nivolumab monograph for professionals. https:\/\/www.drugs.com\/monograph\/nivolumab.html [accessed 6 December 2024]."},{"key":"10.1016\/j.radonc.2026.111494_b0010","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111494_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111494_b0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0035","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111494_b0040","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111494_b0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111494_b0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5230\/jgc.2021.21.e24","article-title":"Successful treatment of advanced gastric cancer with brain metastases through an abscopal effect by radiation and immune checkpoint inhibitor therapy","volume":"21","author":"Muto","year":"2021","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.radonc.2026.111494_b0055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamaoncol.2025.1926","article-title":"Adjuvant chemoradiation and immunotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer: a randomized clinical trial","volume":"11","author":"Xiao","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111494_b0065","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non-small cell lung cancer: the phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0075","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","article-title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial","volume":"25","author":"Mell","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s43856-023-00343-4","article-title":"Phase I\/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer","volume":"3","author":"Mimura","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.radonc.2026.111494_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008385","article-title":"Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer","volume":"12","author":"Mimura","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2026.111494_b0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.radonc.2012.11.002","article-title":"Regression and local control rates after radiotherapy for jugulotympanic paragangliomas: systematic review and meta-analysis","volume":"106","author":"van Hulsteijn","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0095","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.radonc.2026.111494_b0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s10120-018-0899-6","volume":"22","author":"Kato","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.radonc.2026.111494_b0105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(69)92326-5","article-title":"Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer","volume":"2","author":"Moertel","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111494_b0110","first-page":"2324","article-title":"Effect of treatment on outcome","volume":"66","author":"The concept of locally advanced gastric cancer","year":"1990","journal-title":"The Gastrointestinal Tumor Study Group Cancer"},{"key":"10.1016\/j.radonc.2026.111494_b0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4251\/wjgo.v3.i9.131","article-title":"Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer","volume":"3","author":"Koukourakis","year":"2011","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0120","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijrobp.2017.03.032","article-title":"Multicenter phase 2 study of peri-irradiation chemotherapy plus intensity modulated radiation therapy with concurrent weekly docetaxel for inoperable or medically unresectable nonmetastatic gastric cancer","volume":"98","author":"Liu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111494_b0125","series-title":"Perez & Brady\u2019s principles & practice of radiation oncology","author":"Haperin","year":"2019"},{"key":"10.1016\/j.radonc.2026.111494_b0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13014-021-01884-5","article-title":"Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer","volume":"16","author":"Lee","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2006.08.070","article-title":"The role of palliative radiation therapy in symptomatic locally advanced gastric cancer","volume":"67","author":"Tey","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111494_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2026.111494_b0145","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-12-0851","article-title":"Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma","volume":"72","author":"Suzuki","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2026.111494_b0150","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108122","article-title":"HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111494_b0160","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","article-title":"Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer","volume":"121","author":"Yoneda","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2026.111494_b0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","article-title":"Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis","volume":"151","author":"Sha","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0170","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2026.111494_b0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111494_b0180","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2026.111494_b0185","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:05:10Z","timestamp":1789751110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026001337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"alternative-id":["S0167814026001337"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111494","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111494"}}